Pharma News

The next time you hear the words "Meetha patta" or "Madrasi patta", don't ignore the humble heart-shaped popular mouth-freshener. Paan or betel leaf could provide the key to unlock an arsenal of anti-inflammatory drugs, claim Indian researchers.

Regular virtual reality (VR) headset-users who play motion-heavy videos suffer the most from motion sickness and nausea, researchers have found.

Women of reproductive age who are thinking of having children should stay fit. A recent study warns that children born to obese women with diabetes are four times more likely to be diagnosed with autism spectrum disorder.

The US researchers have identified two life-threatening vector-borne diseases that can be passed from mother to child through the placenta.

[adsense:336x280:8701650588]

The U.S. Agency for International Development (USAID) today announced three new awards to support the Government of India’s efforts to end tuberculosis (TB) in India.

AbbVie , in cooperation with Neurocrine Biosciences, Inc. announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo.

OptiNose, a privately-held specialty biopharmaceutical company, announced that its licensing partner, Avanir Pharmaceuticals, Inc. has reported that the U.S. Food & Drug Administration (FDA) approved ONZETRA™ Xsail™ (sumatriptan nasal powder), formerly AVP-825, for the acute treatment of migraine with or without aura in adults. ONZETRA Xsail is the first product developed by OptiNose to receive FDA approval and is an intranasal medication delivery system using the novel Xsail Breath Powered Delivery Device.

Drug development company SCYNEXIS, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track and Qualified Infectious Disease Product (QIDP) designations for the intravenous (IV) formulation of SCY-078, SCYNEXIS' novel antifungal product, for the indications of invasive candidiasis (including candidemia) and invasive aspergillosis. SCYNEXIS is currently conducting a Phase 1 study of the IV formulation of SCY-078 to evaluate the safety, tolerability and pharmacokinetics of single-rising doses. The FDA granted QIDP and Fast Track designations for the oral formulation of SCY-078 for both the treatment of invasive candidiasis and invasive aspergillosis in 2014. The oral formulation is currently in Phase 2 development for both invasive candidiasis and vulvovaginal candidiasis.